Fundamental and translational studies showing that blockade of netrin with NP137 decreased resistance to anti-cancer treatments by inhibiting the EMT, providing strong scientific rational to the on-going combination clinical trial with NP137.
L’équipe de Bernard Hanseeuw a identifié une piste vers un diagnostic d’Alzheimer fiable du vivant de la personne, alors qu’à ce jour, seule une autopsie permet de distinguer cette maladie des autres pathologies neuro-dégénératives.
The 2023 call for "WELBIO Investigator programmes" for fundamental research in the life sciences leading to applications in all fields of (bio)technology will open on 12 September 2023.
14 strategic research programmes in the fields of engineering sciences, chemistry and physics have been selected. The aim? To translate breakthrough innovation into applications that promote sustainable transition.
The year 2022 marked a turning point for our institute with the creation of its new technology department (WEL-T) and a growing societal and economic impact in health (WELBIO).
Congratulations to Philippe Denoël, Head of Vaccines External R&D at GSK, succeeding to Jean Stéphenne to the role of President of the Governing Board of the WEL Research Institute.
Benoit Van den Eynde's team discovered a new fundamental mechanism, using molecules previously used to treat hypertension, which could help the immune system to fight cancer cells more effectively.
From bench to bedside: How an understanding of the mechanisms of vascular development in Miikka Vikkula's lab led to the prenatal treatment of a foetus suffering from a lymphatic malformation by Dr Laurence Boon's team.
For 20 years, Stefan Constantinescu's team has been trying to establish the molecular basis of certain blood cancers (myeloproliferative neoplasms) with several discoveries to their credit.
Laure Bindels and her team showed that altered hepatic AHR receptor signalling could promote liver disorders in cancer cachexia, a syndrome that induces weight loss, muscle wasting and immune deficiency.
Amandine Everard's team demonstrated a causal link between the intestinal microbiota, and more precisely a phenolic metabolite produced by it, and compulsive eating behaviours.
Ana Beloqui and her team developed an oral formulation, based on lipid nanoparticles, of drugs usually administered by subcutaneous injection in the treatment of non-alcoholic fatty liver disease.